Company intelligence / Profile preview

LB Holding

New York City, New York, United Statesannuaire-entreprises.data.gouv.fr ↗

Ownership: Private
Development stage: Other

Overview

Phase II trial of lead candidate LB‑102 demonstrated efficacy and safety comparable to legacy amisulpride with improved delivery. The drug showed favorable tolerability with minimal sedation and moderate weight gain. Company is preparing for Phase III trials and potential expansion into additional indications such as depression and bipolar depression.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculeSynthetic glucocorticoid corticosteroid
Industry: Biotech

Partnerships

None publicly disclosed as major pharma partnerships; investors include Vida Ventures, Pontifax, Deep Track Capital, TCGX.

Beyond the preview

Go deeper on LB Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LB Holding.

Explore the full profile